BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma
| Autor: | Alessia Cimadamore, Monica Amati, Albero Murrone, Federica Pecci, Federica Monaco, Corrado Rubini, Rossana Berardi, Francesca Bianchi, Ilaria Fiordoliva, Valeria Cognigni, Luca Cantini, Marco Tomasetti, Francesca Barbisan, Riccardo Giampieri, Lory Santarelli, Silvia Rinaldi, Cecilia Copparoni |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
BRCA-associated protein 1 (BAP1)
Malignant mesothelioma MicroRNA MiR-31 Prognosis Pulmonary and Respiratory Medicine Oncology Chemotherapy Prognostic factor medicine.medical_specialty BAP1 Multivariate analysis business.industry Pleural mesothelioma Proportional hazards model medicine.medical_treatment mir-31 Internal medicine Cohort Medicine Original Article business |
| Zdroj: | J Thorac Dis |
| ISSN: | 2077-6624 2072-1439 |
| Popis: | Background Malignant pleural mesothelioma (MPM) is an aggressive disease, with few available treatment options. Identification of novel prognostic and predictive biomarkers is a priority. In MPM patients, BRCA-associated protein 1 (BAP1) alterations are detected in about 60% of cases and miR-31 seems to be involved in BAP1 regulation at post-transcriptional level. The aim of this study was to evaluate the interaction between BAP1 and miR-31 in MPM and their prognostic role in MPM. Methods The expression of BAP1 and miR-31 was analyzed in tissues of 55 MPM patients treated with first-line chemotherapy. Overall survival (OS) and progression-free survival (PFS) were assessed by Kaplan-Meier method and Log-rank test was used to investigate differences among subgroups. Multivariate Cox regression analysis was used to evaluate independent predictors of survival. Results In the whole cohort, loss of BAP1 was associated with a significant improvement in OS, but not in PFS. Lower miR-31 levels were detected in epithelioid MPM (e-MPM) compared to the non-epithelioid subtypes and resulted associated with BAP1 loss. By looking at the e-MPM subgroup, loss of BAP1 was not able to predict clinical outcome. Conversely, miR-31 levels were significantly associated with PFS (P=0.028), but not with OS (P=0.059). By combining the two biomarkers, e-MPM patients with BAP1 loss/low miR-31 levels showed a better prognosis compared to the ones with BAP1 retained/high miR-31 levels (median OS 22.6 vs. 17.0 months, P=0.017 and median PFS 8.7 vs. 5.1 months, P=0.020). The BAP1 and miR-31 combination was confirmed at multivariate analysis as an independent prognostic factor for e-MPM patients. Conclusions In this preliminary study, we found that the prognostic stratification of e-MPM patients may be improved by simultaneously assessing of BAP1 status and miR-31 levels. The two-biomarker score is useful to identify a subgroup of e-MPM tumors characterized by BAP1 retained and high miR-31 levels with worse clinical outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|